Patents by Inventor Mildred Enid Acevedo-Duncan
Mildred Enid Acevedo-Duncan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11065266Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.Type: GrantFiled: August 28, 2019Date of Patent: July 20, 2021Assignees: UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Mildred Enid Acevedo-Duncan, Wishrawana Sarathi Ratnayake, David A. Ostrov
-
Patent number: 10918650Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.Type: GrantFiled: June 2, 2017Date of Patent: February 16, 2021Assignees: UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION. INC.Inventors: Mildred Enid Acevedo-Duncan, Wishrawana Ratnayake, David A. Ostrov
-
Publication number: 20200022994Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.Type: ApplicationFiled: August 28, 2019Publication date: January 23, 2020Inventors: Mildred Enid ACEVEDO-DUNCAN, Wishrawana Sarathi RATNAYAKE, David A. OSTROV
-
Publication number: 20170348336Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-? and/or PKC-?. Non-limiting examples of an inhibitor of PKC-? and/or PKC-? include ICA-1 and ACPD. The invention also provides PKC-? and/or PKC-? as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-? and/or PKC-?. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-? and/or PKC-? based on the levels and/or activity of PKC-? and/or and/or PKC-? mRNA or protein in the melanoma cells from the subject are also provided.Type: ApplicationFiled: June 2, 2017Publication date: December 7, 2017Applicant: UNIVERSITY OF SOUTH FLORIDAInventor: Mildred Enid Acevedo-Duncan
-
Patent number: 9351981Abstract: The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1?, 2?, 3?, 4?)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-?/IKK-?, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells.Type: GrantFiled: September 19, 2011Date of Patent: May 31, 2016Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Mildred Enid Acevedo-Duncan, Diondra Denise Hill, David A. Ostrov
-
Publication number: 20160106767Abstract: The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1?, 2?, 3?, 4?)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-?/IKK-?, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells.Type: ApplicationFiled: September 19, 2011Publication date: April 21, 2016Applicants: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: Mildred Enid Acevedo-Duncan, Diondra Denise Hill, David A. Ostrov
-
Patent number: 9301965Abstract: A method of treating ovarian cancer by administering a PKC inhibitor is presented herein. It was found that administering a PKC inhibitor, such as ACPD or ICA-1, to ovarian cancer cells inhibited cancer cell proliferation.Type: GrantFiled: June 19, 2015Date of Patent: April 5, 2016Assignees: University of South Florida, University of Florida Research Foundation, Inc.Inventors: Mildred Enid Acevedo-Duncan, David Ostrov, Minjel Shah, Christopher Apostolatos, Hercules Apostolatos
-
Publication number: 20160003825Abstract: The present invention provides use of protein kinase C-zeta (PKC-?) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.Type: ApplicationFiled: September 23, 2015Publication date: January 7, 2016Applicants: University of South Florida, The United States Government as represented by the Department of Veterans AffairsInventors: Mildred Enid Acevedo-Duncan, Diondra D. Hill
-
Publication number: 20150366883Abstract: A method of treating ovarian cancer by administering a PKC inhibitor is presented herein. It was found that administering a PKC inhibitor, such as ACPD or ICA-1, to ovarian cancer cells inhibited cancer cell proliferation.Type: ApplicationFiled: June 19, 2015Publication date: December 24, 2015Applicants: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., UNIVERSITY OF SOUTH FLORIDAInventors: Mildred Enid Acevedo-Duncan, David Ostrov, Minjel Shah, Christopher Apostolatos, Hercules Apostolatos
-
Patent number: 9078915Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.Type: GrantFiled: November 8, 2013Date of Patent: July 14, 2015Assignees: University of South Florida, The United States of America as represented by the Department of Veterans AffairsInventors: Mildred Enid Acevedo-Duncan, Hla Y. Win, Raoul Salup
-
Publication number: 20140065208Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicants: The United States Government as represented by the Department of Veterans Affairs, UNIVERSITY OF SOUTH FLORIDAInventors: Mildred Enid ACEVEDO-DUNCAN, Hla Y. WIN, Raoul SALUP
-
Publication number: 20130189257Abstract: The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1?, 2?, 3?, 4?)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-?/IKK-?, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells.Type: ApplicationFiled: September 19, 2011Publication date: July 25, 2013Applicants: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: Mildred Enid Acevedo-Duncan, Diondra Denise Hill, David A. Ostrov
-
Patent number: D949580Type: GrantFiled: December 8, 2020Date of Patent: April 26, 2022Assignee: University of South FloridaInventor: Mildred Enid Acevedo-Duncan